Riskpilot← Back to searchSign inGet full accessZOBRIUS PHARMA AS
ASActiveOrg 914330009Tollbugata 49, 3044 DrammenManufacture of other food products n.e.c. · NACE 1089Est. 20141 employees
Revenue 2024
NOK 27K
-94% vs 2023
EBITDA margin
-9777.6%
-74% vs 2023
Equity ratio
71.8%
Financial strength
Net profit 2024
NOK -2,8M
-69% vs 2023
| Revenue | NOK 27K | -94% |
| EBITDA | NOK -2,7M | -74% |
| Net profit | NOK -2,8M | -69% |
| Total assets | NOK 3,4M | +4% |
| Equity | NOK 2,5M | +37% |
| Employees | 1 | — |
Legal name
ZOBRIUS PHARMA AS
Org number
914330009
Legal form
Aksjeselskap
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
21. oktober 2014
Share capital
NOK 2 315 976
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Forskning og utvikling, patentering produksjon og markedsføring av natur- og otc preparater. Finansiering. Videre vil selskapet kunne delta i annen virksomhet som naturlig faller inn under dette.
Address
Tollbugata 49, 3044 Drammen
Phone
+4791765111
Email
post@zobrius.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 99 | 100 | 200 | 69 | 57 | 2 264 | 37 | 128 | 424 | 27 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −808 | −365 | −1 | −54 |
| EBITDA | −32 | 10 | −105 | −1 133 | −2 831 | −2 661 | −6 662 | −3 235 | −1 539 | −2 673 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −106 | −7 | −24 | −30 | −30 |
| EBIT | −32 | 10 | −105 | −1 133 | −2 831 | −2 767 | −6 669 | −3 258 | −1 569 | −2 703 |
| Net financials | 0 | 0 | 0 | 0 | −14 | −101 | −4 | −78 | −90 | −107 |
| Profit before tax | −32 | 10 | −105 | −1 132 | −2 845 | −2 868 | −6 673 | −3 336 | −1 658 | −2 810 |
| Tax | −0 | −0 | −0 | −0 | −94 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −32 | 10 | −105 | −1 132 | −2 751 | −2 868 | −6 673 | −3 336 | −1 658 | −2 810 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 8 | 26 | 91 | 940 | 3 435 | 6 616 | 5 504 | 3 902 | 3 275 | 3 421 |
| Equity | 3 | 20 | 59 | 766 | 1 415 | 3 447 | 2 791 | 1 674 | 1 798 | 2 458 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 500 | 1 500 | 1 500 | 1 500 | 900 | 300 |
| Short-term debt | 5 | 6 | 32 | 174 | 520 | 1 669 | 1 213 | 728 | 578 | 663 |
| Total debt | 5 | 6 | 32 | 174 | 2 020 | 3 169 | 2 713 | 2 228 | 1 478 | 963 |
EBITDA margin
-9777.6%
This company
15.8%
Market median
-61984% vs market
20152024
Equity ratio
71.8%
This company
38.2%
Market median
+88% vs market
20152024
Return on equity
-114.3%
This company
18.4%
Market median
-721% vs market
20152024
Net profit margin
-10278.2%
This company
8.1%
Market median
-126991% vs market
20152024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20152024
Debt / equity
0.39×
This company
0.62×
Market median
+37% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2014-08-25 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SA Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pharma Partner As | Company | 13.5% | 13.5% | 2024 |
| Individual | 12.1% | 12.1% | 2024 | |
Bioactiva Diagnostica Gmbh | Company | 10.8% | 10.8% | 2024 |
Jack J Holding As | Company | 9.4% | 9.4% | 2024 |
Norberg & Partner Sustainable Group | Company | 7.9% | 7.9% | 2024 |
Bsn Invest As | Company | 5.8% | 5.8% | 2024 |
Slaastad Management Consultant As | Company | 5.2% | 5.2% | 2024 |
Vassbygda Industrier As | Company | 4.1% | 4.1% | 2024 |
| Individual | 2.3% | 2.3% | 2024 | |
Magua As | Company | 1.6% | 1.6% | 2024 |
Rodin & Partner Ab | Company | 1.9% | 1.9% | 2024 |
| Individual | 1.8% | 1.8% | 2024 | |
Alpha Eiendom Oslo As | Company | 1.6% | 1.6% | 2024 |
| Individual | 1.6% | 1.6% | 2024 | |
| Individual | 1.5% | 1.5% | 2024 | |
| Individual | 1.4% | 1.4% | 2022 | |
| Individual | 1.1% | 1.1% | 2024 | |
Spånan Invest Ab | Company | 1.1% | 1.1% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZOBRIUS PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steinar Ask Magnussen | Chief Executive Officer | 0 companies |
| Grethe Støa Birketvedt | Board of Directors | 0 companies |
| Astrid Green | Board of Directors | 0 companies |
| Sverre Arne Slaastad | Board of Directors | 0 companies |
| Arvid Helge Lindberg | Board of Directors | 0 companies |
| Børge Skjerven Nygårdshaug | Board of Directors | 0 companies |
| Jack Jensen | Board of Directors | 0 companies |